4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Intellia Therapeutics, Inc. (NTLA) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 377 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NTLA reported $68M in revenue and ($413M) in net income.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Interactive charts & full statements → Open the NTLA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $68M | $58M | $36M | $52M |
| Operating Income (EBIT) | ($441M) | ($534M) | ($515M) | ($458M) |
| Net Income | ($413M) | ($519M) | ($481M) | ($474M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $15M | $23M | $14M | $14M | $17M | — |
| Operating Income (EBIT) | ($100M) | ($99M) | ($112M) | ($110M) | ($121M) | — |
| Net Income | ($96M) | ($96M) | ($101M) | ($101M) | ($114M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $842M | $1.2B | $1.3B | $1.5B | — |
| Total Liabilities | $171M | $319M | $251M | $284M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NTLA viewer.
About TickerBase · Data methodology & sources